mc4r‑deficient obesity

mc4r‑deficient obesity

Clinicians Are Missing 40% Of Semaglutide Gains

40% of the weight-loss benefit of semaglutide is left untapped because most clinicians lack a clear, evidence-based workflow for patients with MC4R-deficient obesity. Without a defined protocol, prescribing patterns fall short, leading to missed outcomes even as trial data show robust efficacy. Medical Disclaimer: This article is for informational purposes